Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Accured Expenses (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Change in Accured Expenses readings, the most recent being -$79000.0 for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 106.11% to -$79000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.0 million, a 46.33% decrease, with the full-year FY2025 number at -$2.0 million, down 46.33% from a year prior.
  • Change in Accured Expenses hit -$79000.0 in Q4 2025 for Aligos Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $9.9 million in Q4 2021 to a low of -$12.4 million in Q2 2022.
  • Median Change in Accured Expenses over the past 5 years was $11500.0 (2021), compared with a mean of -$94950.0.
  • The widest YoY moves for Change in Accured Expenses: up 89600.0% in 2022, down 1242500.0% in 2022.
  • Aligos Therapeutics' Change in Accured Expenses stood at $9.9 million in 2021, then plummeted by 75.76% to $2.4 million in 2022, then plummeted by 63.48% to $872000.0 in 2023, then surged by 48.28% to $1.3 million in 2024, then crashed by 106.11% to -$79000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$79000.0 (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.